MFN2 and cardiomyopathy: The overall MFN2 R400Q MAF of 0.0015 in cardiomyopathy, when compared to MAF of 0.000074 from the gnomAD database, represents ~20-fold over-representation in the combined heart disease populations (p<0.00001).